Will Lewis has led Bridgewater, NJ-based Insmed Incorporated to FDA approval of Arikayce (amikacin liposome inhalation suspension), the first and only medication approved by the FDA for the treatment of nontuberculous mycobacterial (NTM) lung disease, a rare disorder most commonly caused by a group of bacteria called mycobacterium avium complex (MAC). It is thought that 86,000 people are likely to be living with NTM lung disease in the US but these rates are increasing, especially among women and in older age groups.
Insmed CEO On Innovating To Compete In Rare Disease
Leading the company with the only therapy approved for NTM lung disease, Will Lewis tells In Vivo that success comes from giving researchers room to breath, visualizing patient benefit, and sailing into uncharted waters.
